Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
London; NICE; Feb. 1, 2023. 16 p.
Non-conventional
in English
| BIGG - GRADE guidelines
| ID: biblio-1415983
Responsible library:
BR1.1
ABSTRACT
Evidence-based recommendations on nintedanib (Ofev) for treating idiopathic pulmonary fibrosis in adults when forced vital capacity is above 80% predicted. This technology appraisal is for treating idiopathic pulmonary fibrosis in people with a forced vital capacity (FVC) above 80% predicted. Nintedanib is also recommended for people with an FVC between 50% and 80% predicted (NICE technology appraisal guidance 379). Commercial arrangement There is a simple discount patient access scheme for nintedanib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact distribution.bra@boehringer-ingelheim.com for details.
Full text:
Available
Collection:
Tematic databases
Database:
BIGG - GRADE guidelines
Main subject:
Vital Capacity
/
Idiopathic Pulmonary Fibrosis
Type of study:
Practice guideline
/
Prognostic study
/
Risk factors
Language:
English
Year:
2023
Document type:
Non-conventional
